Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 308 participants.

Also called NCT03436693

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 308 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03436693
Other papers using this trial's data
  • Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan Journal of diabetes investigation, 2022-12 DOI, PubMed 35861630, PMC9720226 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03436693. Randomized; quadruple masking; primary purpose treatment. Start 2018-02-15 (actual); primary completion 2021-01-21 (actual). Results posted on 2024-07-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
Condition
Diabetic Nephropathy
Intervention (Drug)
Canagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Tanabe Pharma Corporation (class: industry)

Record details

Record id
cardio:ct-nct03436693
Content hash
3007168f9a17290f860a77c4eec71c5a4abd582bad3da0c76924a80fe05641a5